HEPATIC DRUG CLEARANCE IN CHILDREN WITH LEUKEMIA - CHANGES IN CLEARANCE OF MODEL SUBSTRATES DURING REMISSION-INDUCTION THERAPY

被引：37

作者：

RELLING, MV

CROM, WR

PIEPER, JA

CUPIT, GC

RIVERA, GK

EVANS, WE

机构：

[1] ST JUDE CHILDRENS RES HOSP,DIV PHARMACEUT,CLIN PHARMACOKINET & PHARMACODYNAM SECT,MEMPHIS,TN 38101

[2] UNIV TENNESSEE,CTR HLTH SCI,CTR PEDIATR PHARMACOKINET & THERAPEUT,DEPT CLIN PHARM,MEMPHIS,TN 38163

[3] ST JUDE CHILDRENS RES HOSP,DEPT HEMATOL ONCOL,MEMPHIS,TN 38101

[4] UNIV TENNESSEE,CTR HLTH SCI,DEPT PEDIAT,MEMPHIS,TN 38163

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 1987年 / 41卷 / 06期

关键词：

D O I：

10.1038/clpt.1987.91

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：651 / 660

页数：10

共 53 条

[1] VALUE OF MONITORING PLASMA SALICYLATE LEVELS IN TREATING JUVENILE RHEUMATOID-ARTHRITIS - OBSERVATIONS IN 42 CASES [J].

BARDARE, M ;

CISLAGHI, GU ;

MANDELLI, M ;

SERENI, F .

ARCHIVES OF DISEASE IN CHILDHOOD, 1978, 53 (05) :381-385

[2] DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER [J].

BONADONNA, G ;

VALAGUSSA, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) :10-15

[3] DETERMINANTS OF SERUM ANTIPYRINE HALF-LIVES IN PATIENTS WITH LIVER-DISEASE [J].

BRANCH, RA ;

HERBERT, CM ;

READ, AE .

GUT, 1973, 14 (07) :569-573

[4]

CAESAR J, 1961, CLIN SCI, V21, P43

[5] A DOSE AND TIME RESPONSE ANALYSIS OF THE TREATMENT OF HODGKINS-DISEASE WITH MOPP CHEMOTHERAPY [J].

CARDE, P ;

MACKINTOSH, FR ;

ROSENBERG, SA .

JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (02) :146-153

[6] INDOCYANINE GREEN - OBSERVATIONS ON ITS PHYSICAL PROPERTIES, PLASMA DECAY, AND HEPATIC EXTRACTION [J].

CHERRICK, GR ;

STEIN, SW ;

LEEVY, CM ;

DAVIDSON, CS .

JOURNAL OF CLINICAL INVESTIGATION, 1960, 39 (04) :592-600

[7]

CONNEY AH, 1967, PHARMACOL REV, V19, P317

[8] SIMULTANEOUS ADMINISTRATION OF MULTIPLE MODEL SUBSTRATES TO ASSESS HEPATIC DRUG CLEARANCE [J].

CROM, WR ;

WEBSTER, SL ;

BOBO, L ;

TERESI, ME ;

RELLING, MV ;

EVANS, WE .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (06) :645-650

[9]

CUPIT GC, 1986, DRUG INTEL CLIN PHAR, V20, P460

[10] CAN SEVERE VINCRISTINE NEUROTOXICITY BE PREVENTED [J].

DESAI, ZR ;

VANDENBERG, HW ;

BRIDGES, JM ;

SHANKS, RG .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 8 (02) :211-214

← 1 2 3 4 5 6 →